Duchenne Clinical Trials

61 recruitingLast updated: May 21, 2026

There are 61 actively recruiting duchenne clinical trials across 29 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Little Rock, Arkansas, United States, Atlanta, Georgia, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Duchenne Trials at a Glance

61 actively recruiting trials for duchenne are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Little Rock, Atlanta, and Philadelphia. Lead sponsors running duchenne studies include Italfarmaco, Assistance Publique - Hôpitaux de Paris, and Centre Hospitalier Universitaire de Liege.

About Duchenne Clinical Trials

Looking for clinical trials for Duchenne? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Duchenne trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Duchenne clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 61 trials

Recruiting
Phase 2

Vasodilator and Exercise Study for DMD (VASO-REx)

ExerciseDuchenne Muscular DystrophyDMD+4 more
University of Florida50 enrolled1 locationNCT06290713
Recruiting
Phase 2

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Duchenne Muscular DystrophyDMDNeuromuscular Diseases+2 more
Satellos Bioscience, Inc.51 enrolled21 locationsNCT07287189
Recruiting
Phase 3

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Duchenne Muscular Dystrophy
Solid Biosciences Inc.80 enrolled2 locationsNCT07160634
Recruiting
Phase 1Phase 2

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Duchenne Muscular Dystrophy
Solid Biosciences Inc.60 enrolled15 locationsNCT06138639
Recruiting

The Duchenne Registry

Becker muscular dystrophyDuchenne Muscular DystrophyDystrophinopathy+2 more
The Duchenne Registry10,000 enrolled1 locationNCT02069756
Recruiting
Early Phase 1

Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

Duchenne Muscular Dystrophy (DMD)
Shanghai Siponuoyin Biotechnology Co Ltd9 enrolled1 locationNCT07188012
Recruiting
Phase 1Phase 2

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.18 enrolled1 locationNCT07429240
Recruiting

The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)
University of Rochester105 enrolled1 locationNCT07092540
Recruiting
Phase 1

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy
Insmed Gene Therapy LLC12 enrolled10 locationsNCT06817382
Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cystic FibrosisHuntington DiseaseSickle Cell Disease+12 more
Assistance Publique - Hôpitaux de Paris550 enrolled1 locationNCT06147414
Recruiting

Invasive Home Ventilation in Denmark

Spinal Cord Injuries (SCI)Neuromuscular Diseases (NMD)MSA - Multiple System Atrophy+5 more
Rigshospitalet, Denmark450 enrolled1 locationNCT07467187
Recruiting
Phase 1Phase 2

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy
BioMarin Pharmaceutical18 enrolled8 locationsNCT06280209
Recruiting
Not Applicable

Urinary Titin Biomarker in DMD

Duchenne Muscular Dystrophy (DMD)Becker's Muscular Dystrophy (BMD)
Children's Hospital of Philadelphia50 enrolled1 locationNCT07332013
Recruiting

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

Duchenne Muscular Dystrophy (DMD)Spinal Muscular Atrophy Type 3
Columbia University106 enrolled3 locationsNCT06839469
Recruiting
Phase 1

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Muscular Dystrophy, Duchenne
Sarepta Therapeutics, Inc.83 enrolled7 locationsNCT04626674
Recruiting

DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies

Becker muscular dystrophyCardiomyopathyDuchenne Muscular Dystrophy (DMD)
Aristotle University Of Thessaloniki65 enrolled1 locationNCT07515235
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy
Hoffmann-La Roche50 enrolled25 locationsNCT06450639
Recruiting
Phase 1Phase 2

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

Duchenne Muscular Dystrophy (DMD)
Entrada Therapeutics, Inc.24 enrolled15 locationsNCT07038824
Recruiting
Phase 1Phase 2

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Duchenne Muscular Dystrophy (DMD)
Entrada Therapeutics, Inc.24 enrolled14 locationsNCT07037862
Recruiting
Phase 2

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular DystrophyDMDExon 44
NS Pharma, Inc.20 enrolled25 locationsNCT05996003